MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

Search

Syndax Pharmaceuticals Inc

Затворен

СекторЗдравеопазване

16.45 0.43

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

16.17

Максимум

16.71

Ключови измерители

By Trading Economics

Приходи

13M

-72M

Продажби

18M

38M

Марж на печалбата

-189.28

Служители

270

EBITDA

20M

-64M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+103.65% upside

Дивиденти

By Dow Jones

Следващи печалби

4.11.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

458M

1.4B

Предишно отваряне

16.02

Предишно затваряне

16.45

Настроения в новините

By Acuity

50%

50%

183 / 371 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

Syndax Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

7.10.2025 г., 16:58 ч. UTC

Печалби

BMW Trims 2025 View, Citing Weaker Performance in China

7.10.2025 г., 23:43 ч. UTC

Пазарно говорене

Nikkei May Trade Rangebound; Takaichi's Policy Steps in Focus -- Market Talk

7.10.2025 г., 23:36 ч. UTC

Пазарно говорене

Gold Edges Higher, Supported by Possible Hedging Demand -- Market Talk

7.10.2025 г., 23:19 ч. UTC

Пазарно говорене

Veem Can Secure More Defense Deals Following Northrop Grumman Win -- Market Talk

7.10.2025 г., 22:50 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

7.10.2025 г., 22:50 ч. UTC

Пазарно говорене

RBNZ Should Take the Option of a Bigger Cut -- Market Talk

7.10.2025 г., 22:40 ч. UTC

Пазарно говорене

South32's Alaskan Project Seen Starting Sooner, Worth More After U.S. Deal -- Market Talk

7.10.2025 г., 21:56 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

7.10.2025 г., 21:56 ч. UTC

Пазарно говорене

Australia Shares Set to Start Day Roughly Flat -- Market Talk

7.10.2025 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

7.10.2025 г., 20:44 ч. UTC

Горещи акции

Stocks to Watch Tuesday Recap: Oracle, Dell, Trilogy Metals -- WSJ

7.10.2025 г., 19:42 ч. UTC

Пазарно говорене

Treasury Yields Fall as Data Blackout Continues -- Market Talk

7.10.2025 г., 19:23 ч. UTC

Придобивния, сливания и поглъщания

Private-Equity Stocks Have Gotten Crushed. J.P. Morgan Says This One Is a Buy. -- Barrons.com

7.10.2025 г., 19:07 ч. UTC

Пазарно говорене

Oil Futures Settle Mixed With Higher OPEC+ Supply in View -- Market Talk

7.10.2025 г., 19:02 ч. UTC

Пазарно говорене

U.S. Natural Gas Posts Back-to-Back Gains -- Market Talk

7.10.2025 г., 16:20 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

7.10.2025 г., 16:20 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

7.10.2025 г., 16:20 ч. UTC

Пазарно говорене

Home Depot Extended Pro Desk Hours Could Drive Sales Growth -- Market Talk

7.10.2025 г., 16:15 ч. UTC

Пазарно говорене

AMD's OpenAI Deal Resets Competitive Landscape for Chips -- Market Talk

7.10.2025 г., 16:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

7.10.2025 г., 15:37 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

7.10.2025 г., 15:37 ч. UTC

Пазарно говорене

Markets for Canadian Aluminum Open Up Beyond U.S. -- Market Talk

7.10.2025 г., 15:33 ч. UTC

Пазарно говорене

Gold Rise Tied to Lower Confidence in Dollar Assets -- Market Talk

7.10.2025 г., 15:25 ч. UTC

Пазарно говорене

Canadian Mining Stocks Rally on U.S. Defense Dept. Deal -- Market Talk

7.10.2025 г., 15:15 ч. UTC

Пазарно говорене

Investors Look to Gold, Bitcoin as Traditional Correlations Break Down -- Market Talk

7.10.2025 г., 15:04 ч. UTC

Пазарно говорене

Market Talk Roundup: Latest on U.S. Politics

7.10.2025 г., 15:04 ч. UTC

Пазарно говорене

Canadian Aluminum Exports Squeezed by Tariffs -- Market Talk

7.10.2025 г., 14:56 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

7.10.2025 г., 14:56 ч. UTC

Пазарно говорене

U.S. Government Shutdown May Impact Release of Canadian Trade Data -- Market Talk

7.10.2025 г., 14:52 ч. UTC

Печалби

These Stocks Are Moving the Most Today: Tesla, AMD, Ford, Dell, IBM, AppLovin, Trilogy Metals, Aehr, and More -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

Syndax Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

103.65% нагоре

12-месечна прогноза

Среден 33.5 USD  103.65%

Висок 56 USD

Нисък 17 USD

Според 12 анализатори от Wall Street, предложили 12-месечна ценова цел за Syndax Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

12 ratings

11

Купи

1

Задържане

0

Продай

Техническа оценка

By Trading Central

9.91 / 14.15Подкрепа & съпротива

Краткосрочен план

Very Strong Bearish Evidence

Средносрочен план

Bullish Evidence

Дългосрочен план

Weak Bearish Evidence

Настроение

By Acuity

183 / 371 Класиране в Здравеопазване

Настроения в новините

Neutral

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.
help-icon Live chat